JSW Cement IPO allotment to be finalised today. Check status, GMP and other details
The qualified institutional buyers (QIB) category was subscribed 15.8 times, non-institutional investors (NII) 10.97 times, while the retail portion managed 1.81 times subscription.
In the grey market, JSW Cement shares are quoting at a modest premium of around 4% over the issue price, signalling cautious optimism ahead of listing.
How to check allotment status
Applicants can verify their allotment status through the registrar,
Kfin Technologies
.
Visit the Kfintech IPO allotment status page (
https://ipostatus.kfintech.com/
).
Select 'JSW Cement' from the dropdown list.
Enter your PAN number, application number, or DP/Client ID.
Click 'Search' to view your allotment details.
Investors can also check their IPO allotment status through the BSE website
Go to
https://www.bseindia.com/investors/appli_check.aspx
Select 'Equity' and 'JSW Cement' from the dropdowns.
Enter your application number and PAN.
Click 'Search' to check your status.
Refunds for unallotted applications and credit of shares to successful investors' demat accounts are expected on August 13. The stock is scheduled to list on both the BSE and NSE on August 14.
JSW Cement, part of the JSW Group, is a major manufacturer of green cement, operating seven plants across India with an installed grinding capacity of 20.6 million tonnes per annum.
The IPO comprised a fresh issue of 10.88 crore shares worth Rs 1,600 crore and an offer for sale of 13.61 crore shares worth Rs 2,000 crore by the promoters. The price band was set at Rs 139–147 per share, with a lot size of 102 shares.
Proceeds from the fresh issue will be used to part-finance a new integrated cement unit at Nagaur, Rajasthan, prepay or repay certain borrowings, and for general corporate purposes.
Given the company's recent financial performance — including a loss in FY25 after two profitable years — market watchers believe listing-day moves could depend heavily on broader market sentiment and investor outlook on the cement sector.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
19 minutes ago
- Economic Times
Early-stage VC firm Atomic Capital closes first fund at Rs 400 crore
ETtech Mumbai-based early-stage venture capital fund Atomic Capital has announced the final close of its first fund at Rs 400 crore. The fund will focus on Indian consumer, consumer-tech, and consumer-enabler startups with a target portfolio capacity of 10 to 12 companies. It will invest in startups looking for pre-series A to series A funding rounds that have achieved a product-market fit. Pre-series A and series A funding happens after a startup proves a product-market fit for its offering and gains some traction in the seed stage. The average first cheque will be between Rs 10 crore and Rs 30 crore. Further, it will reserve a portion of the fund for follow-on investments in portfolio companies. Atomic Capital, which was founded by Apoorv Gautam in 2024, had announced the first close of its fund last year at Rs 155 crore. Since then, it has invested about Rs 50 crore across four companies: beauty and personal care startup Conscious Chemist, dairy and foods brand Doodhvale Farms, beverage label Rio Beverages and western apparel brand Anny. Gautam has over 18 years of experience in investing, consulting, and strategic leadership. In the past, he has been associated with Rivigo, McKinsey and Bain.'Our commitment goes beyond capital; we bring hands-on support, strategic know-how, and the conviction that building enduring brands can transform lives and unlock significant value,' said Gautam, founder and managing partner of the fund, in a statement. 'Our focus is on capital-efficient businesses addressing large and expanding markets.'Currently, Atomic Capital is evaluating over 20 startups for investment. 'We have already issued a term sheet for our fifth investment,' said Gautam. "Over the next 2–3 years, we plan to deploy both initial and follow-on capital, aligned with our overall fund timeline of eight years," he fund's investment decision will be based on rapport with the founding team, clear revenue momentum and capital efficiency, Gautam noted, adding, 'We are firm believers in sustainable, capital-efficient growth — it's the cornerstone of building enduring businesses.'Food and beverages, nutraceuticals, beauty and personal care, apparel and footwear, pet care, electronics, ecommerce, SaaS and more are some of the key areas in which the fund is looking to invest in the future. Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. As 50% US tariff looms, 6 key steps that can safeguard Indian economy As big fat Indian wedding slims to budget, Manyavar loses lustre Why are mid-cap stocks fizzling out? It's not just about Trump tariffs. The airport lounge war has begun — and DreamFolks is losing Stock Radar: UNO Minda eyeing fresh 52-week high in next few weeks; check target and stop loss for long positions Buy, Sell or Hold: Antique recommends buy on Siemens; Avendus upgrades SBI to Buy post June quarter results Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25% Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Atomic Capital closes ₹400 cr first fund for early growth consumer startups
Atomic Capital, an early growth investment fund, on Tuesday announced the final close of its maiden fund with a corpus of Rs 400 crore. With its first fund, the venture capital firm plans to invest in early growth-stage homegrown consumer, consumer-tech, and consumer-enabler startups. Focus areas include food and beverages, nutraceuticals, personal care and beauty, jewellery, pet care, electronics accessories, and home furnishing. Investment strategy and portfolio plans With an average first cheque size of Rs 10–30 crore, the fund aims to build a portfolio of 10–12 companies, with a portion of the corpus reserved for follow-on investments, the firm said in a statement. It will evaluate startups that have achieved product–market fit and are seeking to raise from a pre-Series A to a Series A round. The fund reached its first close at Rs 155 crore in 2024. Over the past 12 months, Atomic Capital invested nearly Rs 50 crore across four startups — beauty and personal care company ConsciousChemist, dairy and foods firm Doodhvale Farms, beverage company Rio Beverages, and women's western apparel brand Anny. Capital deployment and pipeline In the next three years, the fund plans to deploy initial and follow-on capital, aligned with its eight-year timeline. 'We are currently evaluating over 20 companies and have already issued a term sheet for our fifth investment,' the company said. Apoorv Gautam, founder and managing partner of the firm, said the fund's commitment extends beyond capital to include hands-on support, strategic expertise, and the belief that building enduring brands can transform lives and unlock significant value. 'Our focus is on capital-efficient businesses addressing large and expanding markets. Additionally, our investment decisions are driven by a strong rapport with the founding team, clear revenue momentum, and disciplined capital efficiency. We are firm believers in sustainable, capital-efficient growth — it's the cornerstone of building enduring businesses,' Gautam said.
Business Standard
20 minutes ago
- Business Standard
Sensex, Nifty trade lower; pharma shares climb for 2nd day
The key equity indices traded with moderate losses in mid-afternoon trade. Market participants will closely track crude oil prices, FII activity, and developments on the tariff front, while awaiting CPI data, scheduled for later today. The Nifty traded near 24,550 mark. Pharma shares advanced for the second consecutive trading session. At 14:25 IST, the barometer index, the S&P BSE Sensex declined 188.02 points or 0.23% to 80,420.40. The Nifty 50 index fell 37.50 points or 0.15% to 24,546.80. In the broader market, the S&P BSE Mid-Cap index shed 0.03% and the S&P BSE Small-Cap index rose 0.10%. The market breadth was negative. On the BSE, 2,131 shares rose and 1,865 shares fell. A total of 153 shares were unchanged. Buzzing Index: The Nifty Pharma index rose 0.96% to 21,811.35. The index rose 1.91% in the past two trading session. Alkem Laboratories (up 7.24%), Granules India (up 4.3%), Biocon (up 4.27%), Ipca Laboratories (up 4.26%) and Abbott India (up 2.08%) were the top gainers. Among the other gainers were Sun Pharmaceutical Industries (up 1.7%), Ajanta Pharma (up 1.54%), Aurobindo Pharma (up 1.41%), Glenmark Pharmaceuticals (up 1.12%) and Laurus Labs (up 1.02%) surged. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.56% to 6.464 from the previous close of 6.428. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 87.6300 compared with its close of 87.7500 during the previous trading session. MCX Gold futures for 3 October 2025 settlement fell 0.24% to Rs 100,080. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.01% to 98.52. The United States 10-year bond yield shed 0.16% to 4.278. In the commodities market, Brent crude for October 2025 settlement declined 6 cents or 0.09% to $66.57 a barrel. Stocks in Spotlight: Abbott India gained 1.96% after the companys standalone net profit climbed 11.53% to Rs 365.86 crore on 11.60% increase in revenue from operations to Rs 1,738.35 crore in Q1 FY26 over Q1 FY25. Kirloskar Industries declined 2.48% after the company reported a 1.73% decrease in consolidated net profit to Rs 95.48 crore in Q1 FY26 as against Rs 97.09 crore reported in Q4 FY25. Revenue from operations fell 2.42% quarter-on-quarter (QoQ) to Rs 1,705.48 crore in the quarter ended 30 June 2025. Praj Industries declined 7.29% after the companys consolidated net profit declined 93.7% to Rs 5.34 crore on 8.4% fall in net sales to Rs 640.20 crore in Q1 FY26 over Q1 FY25.
